The DOI matches its Crossref record, with a small difference in title or year; 54 of the 56 references it cites were found in a registry or an index.
Antidepressant Drug Effects and Depression Severity: A Patient-Level Meta-analysis
Open accessAbstract
CONTEXT: Antidepressant medications represent the best established treatment for major depressive disorder, but there is little evidence that they have a specific pharmacological effect relative to pill placebo for patients with less severe depression. OBJECTIVE: To estimate the relative benefit of medication vs placebo across a wide range of initial symptom severity in patients diagnosed with depression. DATA SOURCES: PubMed, PsycINFO, and the Cochrane Library databases were searched from January 1980 through March 2009, along with references from meta-analyses and reviews. STUDY SELECTION: Randomized placebo-controlled trials of antidepressants approved by the Food and Drug Administration in the treatment of major or minor depressive disorder were selected. Studies were included if their authors provided the requisite original data, they comprised adult outpatients, they included a medication vs placebo comparison for at least 6 weeks, they did not exclude patients on the basis of a placebo washout period, and they used the Hamilton Depression Rating Scale (HDRS). Data from 6 studies (718 patients) were included. DATA EXTRACTION: Individual patient-level data were obtained from study authors. RESULTS: Medication vs placebo differences varied substantially as a function of baseline severity. Among patients with HDRS scores below 23, Cohen d effect sizes for the difference between medication and placebo were estimated to be less than 0.20 (a standard definition of a small effect). Estimates of the magnitude of the superiority of medication over placebo increased with increases in baseline depression severity and crossed the threshold defined by the National Institute for Clinical Excellence for a clinically significant difference at a baseline HDRS score of 25. CONCLUSIONS: The magnitude of benefit of antidepressant medication compared with placebo increases with severity of depression symptoms and may be minimal or nonexistent, on average, in patients with mild or moderate symptoms. For patients with very severe depression, the benefit of medications over placebo is substantial.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“antidepressants have been demonstrated efficient in treating MDD”
From SSRI Treatment Response Prediction in Depression Based on Brain Activation by Emotional Stimuli (2020) · cites this paper as [1]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Fournier and colleagues meta-analysed trials of selective serotonin reuptake inhibitors and estimated the effect size.45 For mild to severe depression the effect estimates ranged from -0.17 to -0.11; this is lower than the effect size for smoking cessation.”
From Change in mental health after smoking cessation: systematic review and meta-analysis (2014) · cites this paper as [45]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“For SSRIs, researchers have argued that a substantial portion of the perceived therapeutic benefit in double-blind randomized clinical trials (RCTs) may stem from placebo responses rather than the drug itself (Sugarman et al., 2014; Fournier et al., 2010; Kirsch, 2014; Moncrieff and Kirsch, 2015).”
From Revisiting the SSRI vs. placebo debate in the treatment of social anxiety disorder: the role of expectancy effects, neural responsivity, and monoamine transporters (2025) · cites this paper as Fournier et al., 2010
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The introduction and widespread use of selective serotonine uptake inhibitors (SSRI) [22, 23] and psychological therapy including cognitive behavioral therapy (CBT) [24, 25] meant that well tolerated and effective treatments for depression and anxiety disorders became available in primary care, widening the group of individuals eligible for treatment.”
From Trends in psychiatric diagnoses, medications and psychological therapies in a large Swedish region: A population-based study (2020) · cites this paper as [23]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“there are differences in individual response”
From SSRI Treatment Response Prediction in Depression Based on Brain Activation by Emotional Stimuli (2020) · cites this paper as [1]
The cited source says what the claim attributes to it.
In the citing paper
“In addition, the effect sizes are generally higher than those obtained for pharmacological treatment of mild-to-moderate depression [34]”
From One-Day Acceptance and Commitment Therapy Compared to Support for Depressed Migraine Patients: a Randomized Clinical Trial. (2020) · cites this paper as [34]
In the citing paper
“Two individual participant data meta-analysis (26, 27) indicated that patients with lower baseline severity would achieve smaller improvement compared to placebo.”
In the citing paper
“Individual-level meta-analyses have found a direct relationship between the magnitude of depressive symptoms and the effectiveness of antidepressants.8–10”
In the citing paper
“Thus, the benefits of antidepressants in non-severe depression have been argued to be minimal.8 11”
In the citing paper
“One small individual patient data meta-analysis found support for increasing benefit with increasing severity of depression,20 but three larger individual patient data meta-analyses did not find any such effect of antidepressants compared with placebo on depression severity .44–46”
From Should antidepressants be used for major depressive disorder? (2020) · cites this paper as [20]
In the citing paper
“For example, meta-analysis has demonstrated that antidepressants, though widely prescribed as a treatment for MDD, may be no more effective than placebo for mild to moderate levels of symptom severity; clinically significant benefits are only observed at “very severe” levels of impairment (18).”
From Depression in diabetes: have we been missing something important? (2011) · cites this paper as [18]
In the citing paper
“For example, meta-analysis has demonstrated that antidepressants, though widely prescribed as a treatment for MDD, may be no more effective than placebo for mild to moderate levels of symptom severity; clinically significant benefits are only observed at “very severe” levels of impairment (18).”
From Depression in diabetes: have we been missing something important? (2011) · cites this paper as [18]
In the citing paper
“Although antidepressants are unlikely to be effective in most presentations of distress (18), physical activity, psychotherapeutic approaches, and discussions with diabetes team members can be effective.”
From Depression in diabetes: have we been missing something important? (2011) · cites this paper as [18]
In the citing paper
“The strength of the pooled standardised mean difference in change was clinically important - the association between smoking cessation and change in depression and anxiety was equal to or larger than the estimate from trials of antidepressants versus placebo.”
From An application of the stress-diathesis model: A review about the association between smoking tobacco, smoking cessation, and mental health (2023) · cites this paper as Fournier et al., 2010
In the citing paper
“A meta-analysis of individual-level data from randomised controlled trials (RCTs) of antidepressants for”
From An application of the stress-diathesis model: A review about the association between smoking tobacco, smoking cessation, and mental health (2023) · cites this paper as Fournier et al., 2010
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Statistical Power Analysis for the Behavioral Sciences
Muller, K. E., & Cohen, J. (1989) · Technometrics · doi:10.2307/1270020 · Cited by 99,603
Statistical power analysis for the behavioral sciences
Cohen, J. (1990) · Computers Environment and Urban Systems · doi:10.1016/0198-9715(90)90050-4 · Cited by 65,417
Statistical Power Analysis for the Behavioral Sciences (2nd ed.).
Lachenbruch, P. A., & Cohen, J. (1989) · Journal of the American Statistical Association · doi:10.2307/2290095 · Cited by 37,421
Hamilton, M. (1960) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.23.1.56 · Cited by 32,817
Kirsch, I., Deacon, B. J., Huedo-Medina, T. B., Scoboria, A., Moore, T. J., & Johnson, B. T. (2008) · PLoS Medicine · doi:10.1371/journal.pmed.0050045 · Cited by 2,442
Selective publication of antidepressant trials and its influence on apparent efficacy
Turner, E. H., Matthews, A. M., Linardatos, E., Tell, R. A., & Rosenthal, R. (2008) · New England Journal of Medicine · doi:10.1056/nejmsa065779 · Cited by 2,435
Elkin, I. (1989) · Archives of General Psychiatry · doi:10.1001/archpsyc.1989.01810110013002 · Cited by 2,300
Dimidjian, S., Hollon, S. D., Dobson, K. S., Schmaling, K. B., Kohlenberg, R. J., Addis, M. E., Gallop, R., McGlinchey, J. B., Markley, D. K., Gollan, J. K., et al. (2006) · Journal of Consulting and Clinical Psychology · doi:10.1037/0022-006x.74.4.658 · Cited by 1,607
Self-citationOstwald, P. F. (1960) · American Journal of Psychotherapy · doi:10.1176/appi.psychotherapy.1960.14.4.817 · Cited by 1,422
The Hamilton Depression Rating Scale: Has the Gold Standard Become a Lead Weight?
Bagby, R. M., Ryder, A. G., Schuller, D. R., & Marshall, M. B. (2004) · American Journal of Psychiatry · doi:10.1176/appi.ajp.161.12.2163 · Cited by 1,148
Research works printed but not linked: 1
- [3]Depression Guideline Panel Depression in primary care: Vol. 2. Treatment of major depression Clinical Practice Guideline No. 5. AHCPR Publication No. 93-0551 Rockville, MD U.S. Department of Health and Human Services, Public Health Service, Agency for Health Care Policy and Research 1993
Cited by
Sorted by citations
Items 801–900 of 1,006
McCarron, R. M., Vanderlip, E. R., & Rado, J. T. (2016) · Annals of Internal Medicine · doi:10.7326/aitc201610040 · Cited by 26
Han, L., McCusker, J., Cole, M., Čapek, R., & Abrahamowicz, M. (2011) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e318221b2f8 · Cited by 21
Gonon, F. (2013) · L information psychiatrique · doi:10.1684/ipe.2013.1054 · Cited by 31
Levine, S. Z., & Leucht, S. (2014) · Schizophrenia Research · doi:10.1016/j.schres.2014.04.005 · Cited by 20
Which placebo to cure depression? A thought-provoking network meta-analysis
Naudet, F., Millet, B., Charlier, P., Reymann, J. M., Maria, A. S., & Falissard, B. (2013) · BMC Medicine · doi:10.1186/1741-7015-11-230 · Cited by 24
Effort-Reward Imbalance and Affective Disorders
Rugulies, R., Aust, B., & Madsen, I. E. H. (2016) · Aligning perspectives on health, safety and well-being · doi:10.1007/978-3-319-32937-6_6 · Cited by 22
Potential of St John's Wort for the Treatment of Depression: The Economic Perspective
Solomon, D., Ford, E., Adams, J., & Graves, N. (2010) · Australian & New Zealand Journal of Psychiatry · doi:10.3109/00048674.2010.526094 · Cited by 21
Pilon, D., Sheehan, J. J., Szukis, H., Morrison, L., Zhdanava, M., Lefèbvre, P., & Joshi, K. (2019) · Journal of Affective Disorders · doi:10.1016/j.jad.2019.04.100 · Cited by 21
Albert, U., Lamba, P., & Stahl, S. M. (2021) · CNS Spectrums · doi:10.1017/s1092852921000304 · Cited by 19
Nielsen, M., & Gøtzsche, P. C. (2011) · International Journal of Risk & Safety in Medicine · doi:10.3233/jrs-2011-0526 · Cited by 23
Pharmacological Treatment of Unipolar Depression
Anderson, I. M. (2012) · Current topics in behavioral neurosciences · doi:10.1007/7854_2012_208 · Cited by 21
Measuring Outcomes in Adult Outpatient Psychiatry
Blais, M. A., Sinclair, S. J., Baity, M. R., Worth, J. L., Weiss, A. P., Ball, L. A., & Herman, J. B. (2011) · Clinical Psychology & Psychotherapy · doi:10.1002/cpp.749 · Cited by 21
On the future of psychodynamic therapy research
Barber, J. P., & Sharpless, B. A. (2015) · Psychotherapy Research · doi:10.1080/10503307.2014.996624 · Cited by 28
Improving work outcomes of dysthymia (persistent depressive disorder) in an employed population
Adler, D. A., Lerner, D., Visco, Z. L., Greenhill, A., Chang, H., Cymerman, E., Azocar, F., & Rogers, W. H. (2015) · General Hospital Psychiatry · doi:10.1016/j.genhosppsych.2015.04.001 · Cited by 23
Hunter, A. M., Cook, I. A., & Leuchter, A. F. (2010) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e3181faa474 · Cited by 21
Enhanced Responsiveness to Selective Serotonin Reuptake Inhibitors during Lactation
Jury, N. J., McCormick, B. A., Horseman, N. D., Benoit, S. C., & Gregerson, K. A. (2015) · PLoS ONE · doi:10.1371/journal.pone.0117339 · Cited by 23
Searle, A., Haase, A. M., Chalder, M., Fox, K. R., Taylor, A. H., Lewis, G., & Turner, K. M. (2013) · Journal of Health Psychology · doi:10.1177/1359105313493648 · Cited by 35
The public health impact of antidepressants: An instrumental variable analysis
Mojtabai, R. (2011) · Journal of Affective Disorders · doi:10.1016/j.jad.2011.05.037 · Cited by 20
Kravdal, Ø., Grundy, E. M. D., & Skirbekk, V. (2015) · Aging & Mental Health · doi:10.1080/13607863.2015.1118010 · Cited by 20
Support for the efficacy of behavioural activation in treating anxiety in breast cancer patients
Hopko, D. R., Lejuez, C. W., Ryba, M. M., Shorter, R. L., & Bell, J. L. (2016) · Clinical Psychologist · doi:10.1111/cp.12083 · Cited by 21
Cosgrove, L., Shaughnessy, A. F., Peters, S. M., Lexchin, J., Bursztajn, H. J., & Bero, L. A. (2017) · Psychotherapy and Psychosomatics · doi:10.1159/000458727 · Cited by 20
¡HOLA, Amigos! Toward Preventing Anxiety and Depression in Older Latinos
Jimenez, D. E., Syed, S. A., Perdomo-Johnson, D., & Signorile, J. F. (2017) · American Journal of Geriatric Psychiatry · doi:10.1016/j.jagp.2017.06.020 · Cited by 21
The overprescription of antidepressants and its impact on the elderly in Australia
Alduhishy, M. (2018) · Trends in Psychiatry and Psychotherapy · doi:10.1590/2237-6089-2016-0077 · Cited by 23
Doyle, F., Freedland, K. E., Carney, R. M., de Jonge, P., Dickens, C. M., Pedersen, S. S., Sørensen, J. R., & Dempster, M. (2019) · Systematic Reviews · doi:10.1186/s13643-019-0985-9 · Cited by 18
Čolić, L., von Düring, F., Denzel, D., Demenescu, L. R., Lord, A., Martens, L., Lison, S., Frommer, J., Vogel, M., Kaufmann, J., et al. (2019) · Biological Psychiatry Cognitive Neuroscience and Neuroimaging · doi:10.1016/j.bpsc.2019.04.003 · Cited by 22
Whitlock, M., Woodward, P. W., & Alexander, R. (2019) · PubMed Central · Cited by 21
Research waste‐related editorial policies of leading dental journals: Situation 2018
Almaqrami, B. S., Hua, F., Liu, Y., & He, H. (2019) · Oral Diseases · doi:10.1111/odi.13257 · Cited by 22
Guo, X., McCutcheon, R. A., Pillinger, T., Mizuno, Y., Natesan, S., Brown, K., & Howes, O. D. (2020) · Journal of Affective Disorders · doi:10.1016/j.jad.2020.07.102 · Cited by 22
Evolutionary theory and the treatment of depression: It is all about the squids and the sea bass
Hollon, S. D., Andrews, P. W., Singla, D. R., Maslej, M. M., & Mulsant, B. H. (2021) · Behaviour Research and Therapy · doi:10.1016/j.brat.2021.103849 · Cited by 22
Self-citationBoffin, N., Bossuyt, N., Declercq, T., Vanthomme, K., & Casteren, V. V. (2012) · Family Practice · doi:10.1093/fampra/cms024 · Cited by 21
Bauer, A. M., Azzone, V., Alexander, L., Goldman, H. H., Unützer, J., & Frank, R. G. (2011) · General Hospital Psychiatry · doi:10.1016/j.genhosppsych.2011.08.019 · Cited by 21
Efficacy of antidepressants: bias in randomized clinical trials and related issues
Wang, S.-M., Han, C., Lee, S.-J., Jun, T.-Y., Patkar, A. A., Masand, P. S., & Pae, C.-U. (2018) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2017.1377070 · Cited by 20
Feng, X.-Z., Li, Z., Li, Z.-Y., Wang, K., Tan, X. N., Zhao, Y.-Y., Mi, W., Zhu, W.-L., Bao, Y., Lü, L., et al. (2023) · Psychiatry Research · doi:10.1016/j.psychres.2023.115637 · Cited by 20
Clinical depression: an evidence-based integrative complementary medicine treatment model.
Sarris, J. J. (2011) · PubMed · Cited by 20
Using Photovoice to explore patients' experiences with mental health medication: A pilot study
Werremeyer, A. B., Kelly, G. A., & Skoy, E. T. (2016) · Mental Health Clinician · doi:10.9740/mhc.2016.05.142 · Cited by 22
Nakagawa, A., Williams, A., Sado, M., Oguchi, Y., Mischoulon, D., Smith, F. A., Mimura, M., & Sato, Y. (2015) · Psychiatry and Clinical Neurosciences · doi:10.1111/pcn.12273 · Cited by 20
Barriers to the Treatment of Mental Illness in Primary Care Clinics in Israel
Ayalon, L., Karkabi, K., Bleichman, I., Fleischmann, S., & Goldfracht, M. (2015) · Administration and Policy in Mental Health and Mental Health Services Research · doi:10.1007/s10488-015-0634-0 · Cited by 20
Impact of Identification and Treatment of Depression in Heart Transplant Patients
Okwuosa, I. S., Pumphrey, D., Puthumana, J. J., Brown, R.-M., & Cotts, W. (2014) · Cardiovascular Psychiatry and Neurology · doi:10.1155/2014/747293 · Cited by 20
Anti-neuropeptide Y plasma immunoglobulins in relation to mood and appetite in depressive disorder
Garcia, F. D., Coquerel, Q., do-Rego, J.-C., Cravezic, A., Bôle‐Feysot, C., Kiive, E., Déchelotte, P., Harro, J., & Fetissov, S. O. (2012) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2012.01.015 · Cited by 20
Sreeharan, V., Madden, H., Lee, J. T., Millett, C. J., & Majeed, A. (2013) · British Journal of General Practice · doi:10.3399/bjgp13x671641 · Cited by 20
Barriers of Chinese primary care attenders to seeking help for psychological distress in Hong Kong
Sun, K. S., Lam, T. P., Lam, K. F., Lo, T. L., Chao, D. V. K., & Lam, E. W. W. (2016) · Journal of Affective Disorders · doi:10.1016/j.jad.2016.02.041 · Cited by 20
A Drug-Centric View of Drug Development: How Drugs Spread from Disease to Disease
Rodriguez‐Esteban, R. (2016) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1004852 · Cited by 20
Gravensteen, I. K., Ekeberg, Ø., Thiblin, I., Helweg‐Larsen, K., Hem, E., Rogde, S., & Tøllefsen, I. M. (2019) · BMC Psychiatry · doi:10.1186/s12888-019-2015-9 · Cited by 20
Vilches, S., Tuson, M., Vieta, E., Álvarez, E., & Espadaler, J. (2019) · Pharmaceutics · doi:10.3390/pharmaceutics11090453 · Cited by 21
Rajakannan, T., Safer, D. J., Burcu, M., & ZITO, J. M. (2015) · Psychiatric Services · doi:10.1176/appi.ps.201500045 · Cited by 21
Public Beliefs About Mental Illness
Schnittker, J. (2012) · Handbooks of sociology and social research · doi:10.1007/978-94-007-4276-5_5 · Cited by 21
Goodman, S. H., & Dimidjian, S. (2012) · The Canadian Journal of Psychiatry · doi:10.1177/070674371205700903 · Cited by 20
Self-citationGoldstein, L. A., Mandel, A. A., DeRubeis, R. J., & Strunk, D. R. (2020) · Behaviour Research and Therapy · doi:10.1016/j.brat.2020.103608 · Cited by 19
Self-citationSarris, J. J., Stough, C. K. K., Bousman, C., Murphy, J., Savage, K. M., Smith, D. J., Menon, R., Chamoli, S., Oliver, G., Berk, M., et al. (2015) · Advances in Integrative Medicine · doi:10.1016/j.aimed.2015.02.001 · Cited by 19
Tancredi, D. J., Slee, C. K., Jerant, A. F., Franks, P. J., Nettiksimmons, J., Cipri, C. S., Gottfeld, D., Huerta, J., Feldman, M. D., Jackson‐Triche, M., et al. (2013) · BMC Health Services Research · doi:10.1186/1472-6963-13-141 · Cited by 19
A randomized controlled trial on an aerobic exercise programme for depression outpatients
Cheung, L. K., & Lee, S. (2018) · Sport Sciences for Health · doi:10.1007/s11332-017-0423-0 · Cited by 20
Rek, K., Kappelmann, N., Zimmermann, J., Rein, M., Egli, S., & Kopf‐Beck, J. (2022) · Psychological Medicine · doi:10.1017/s0033291722001209 · Cited by 22
Zhao, T., Tang, C., Huang, Y., Lu, Q., Guo, M., & Wang, H. (2023) · International Journal of Nursing Studies · doi:10.1016/j.ijnurstu.2023.104452 · Cited by 19
Pitanupong, J., & Sammathit, J. (2023) · BMC Psychiatry · doi:10.1186/s12888-023-04706-y · Cited by 19
Antidepressants in primary care: limited value at the first visit
Arroll, B., Roskvist, R. P., Moir, F., Harwood, M. L. N., Eggleton, K. S., Dowrick, C. F., & Cuijpers, P. J. (2023) · World Psychiatry · doi:10.1002/wps.21057 · Cited by 19
Primary care physicians’ and psychiatrists’ approaches to treating mild depression
Lawrence, R. E., Rasinski, K. A., Yoon, J. D., Meador, K. G., Koenig, H. G., & Curlin, F. A. (2012) · Acta Psychiatrica Scandinavica · doi:10.1111/j.1600-0447.2012.01887.x · Cited by 18
Are antidepressants useful in the treatment of minor depression
Hegerl, U., Schönknecht, P., & Mergl, R. (2011) · Current Opinion in Psychiatry · doi:10.1097/yco.0b013e32834dc15d · Cited by 19
Pharmacological Management of Depression in Patients with Cancer: Practical Considerations
Torta, R., & Ieraci, V. (2013) · Drugs · doi:10.1007/s40265-013-0090-7 · Cited by 20
Stigma and discrimination: A socio-cultural etiology of mental illness.
Levy, B., Celen‐Demirtas, S., Surguladze, T., & Sweeney, K. K. (2014) · The Humanistic Psychologist · doi:10.1080/08873267.2014.893513 · Cited by 27
The media and intellectuals' response to medical publications: the anti-depressants' case
Fountoulakis, K. Ν., Höschl, C., Kasper, S. F., López-Ibor, J. J., & Möller, H. (2013) · Annals of General Psychiatry · doi:10.1186/1744-859x-12-11 · Cited by 18
Multimorbidity and depression treatment
Vyas, A., & Sambamoorthi, U. (2011) · General Hospital Psychiatry · doi:10.1016/j.genhosppsych.2011.02.009 · Cited by 19
Salaminios, G., Duffy, L., Ades, A. E., Araya, R., Button, K. S., Churchill, R. C., Croudace, T. J., Derrick, C., Dixon, P., Dowrick, C. F., et al. (2017) · Trials · doi:10.1186/s13063-017-2253-4 · Cited by 19
The American Psychiatric Association’s Guideline for Major Depressive Disorder: A Commentary
Cosgrove, L., Shaughnessy, A. F., Wheeler, E. E., Austad, K., Kirsch, I., & Bursztajn, H. J. (2012) · Psychotherapy and Psychosomatics · doi:10.1159/000335523 · Cited by 19
McGeary, J. E., Gurel, V., Knopik, V. S., Spaulding, J., & McMichael, J. C. (2011) · Neuropeptides · doi:10.1016/j.npep.2011.06.002 · Cited by 19
Treatment Resistance and Psychodynamic Psychiatry: Concepts Psychiatry Needs from Psychoanalysis
Plakun, E. M. (2012) · Psychodynamic Psychiatry · doi:10.1521/pdps.2012.40.2.183 · Cited by 20
Improving the Capacity to Treat Depression using Talking Therapies
Dunn, B. D., & Roberts, H. (2016) · Wiley eBooks · doi:10.1002/9781118468197.ch13 · Cited by 19
Depression screening and management in primary care
Kroenke, K. (2017) · Family Practice · doi:10.1093/fampra/cmx129 · Cited by 20
Funderburk, J. S., Pigeon, W. R., Shepardson, R. L., Wade, M., Acker, J., Fivecoat, H., Wray, L. O., & Maisto, S. A. (2021) · Journal of Affective Disorders · doi:10.1016/j.jad.2021.01.033 · Cited by 19
Glannon, W. (2018) · doi:10.1093/med/9780198758853.001.0001 · Cited by 29
Blood transcriptional response to treatment-resistant depression during electroconvulsive therapy
Israel‐Elgali, I., Hertzberg, L., Shapira, G., Segev, A., Krieger, I., Nitzan, U., Bloch, Y., Pillar, N., Mayer, O., Weizman, A., et al. (2021) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2021.06.039 · Cited by 20
Patten, R. V., Iverson, G. L., Terry, D. P., Levi, C. R., & Gardner, A. J. (2021) · Frontiers in Neurology · doi:10.3389/fneur.2021.676762 · Cited by 17
Zhang, T., Zhang, J., Huang, J., Zheng, Z., & Wang, P. (2021) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2021.669533 · Cited by 20
Controversies in the Pharmacotherapy of Adolescent Depression
Masi, G. (2022) · Current Pharmaceutical Design · doi:10.2174/1381612828666220526150153 · Cited by 23
Time of day influences stress hormone response to ketamine
Birnie, M. T., Eapen, A. V., Kershaw, Y. M., Lodge, D., Collingridge, G. L., Conway-Campbell, B. L., & Lightman, S. L. (2022) · Journal of Neuroendocrinology · doi:10.1111/jne.13194 · Cited by 18
Kan, H., Peng, W., Wu, C., Wang, D., Lee, M. T., Lee, Y., Chu, T., & Ho, Y. (2022) · Psychopharmacology · doi:10.1007/s00213-022-06250-1 · Cited by 19
Liking of salt is associated with depression, anxiety, and stress
Ferraris, C., Scarlett, C. J., Bucher, T., & Beckett, E. (2023) · Chemical Senses · doi:10.1093/chemse/bjad038 · Cited by 18
Brišnik, V., Vukas, J., Jung‐Sievers, C., Lukaschek, K., Alexander, G. C., Thiem, U., Thürmann, P., Schüle, C., Fischer, S., Baum, E., et al. (2024) · BMC Medicine · doi:10.1186/s12916-024-03397-w · Cited by 21
Initial Severity Effects on Residual Symptoms in Response and Remission
Madhoo, M., & Levine, S. Z. (2015) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000000354 · Cited by 18
Fancher, T. L., & Kravitz, R. L. (2010) · Annals of Internal Medicine · doi:10.7326/0003-4819-152-9-201005040-01005 · Cited by 20
Corticosterone Facilitates Fluoxetine-Induced Neuronal Plasticity in the Hippocampus
Kobayashi, K., Ikeda, Y., Asada, M., Inagaki, H., Kawada, T., & Suzuki, H. (2013) · PLoS ONE · doi:10.1371/journal.pone.0063662 · Cited by 19
Kassan, M., Lasker, G. F., Sikka, S. C., Mandava, S. H., Gökçe, A., Matrougui, K., Hellstrom, W. J. G., Kadowitz, P. J., & Şerefoğlu, E. C. (2013) · Urology · doi:10.1016/j.urology.2013.07.037 · Cited by 19
Thase, M. E. (2011) · Current Psychiatry Reports · doi:10.1007/s11920-011-0235-x · Cited by 20
Back to the future of psychopharmacology: A perspective on animal models in drug discovery
Hendriksen, H., & Groenink, L. (2015) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2015.03.020 · Cited by 18
Bazzan, A. J., Zabrecky, G. P., Monti, D., & Newberg, A. B. (2014) · Expert Review of Neurotherapeutics · doi:10.1586/14737175.2014.892420 · Cited by 18
Young, A., Marriott, B. P., Champagne, C. M., Hawes, M. R., Montain, S. J., Johannsen, N. M., Berry, K., & Hibbeln, J. R. (2017) · British Journal Of Nutrition · doi:10.1017/s0007114517001003 · Cited by 18
DNA methylation and genetic variation of the angiotensin converting enzyme (ACE) in depression
Lam, D., Ancelin, M., Ritchie, K. A., Saffery, R., & Ryan, J. L. (2017) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2017.11.003 · Cited by 18
A rapid, Web-based method for obtaining patient views on effects and side-effects of antidepressants
Rizo, C., Deshpande, A., Ing, A., & Seeman, N. (2010) · Journal of Affective Disorders · doi:10.1016/j.jad.2010.07.027 · Cited by 18
Approaches to decrease the prevalence of depression in later life
Almeida, O. P. (2012) · Current Opinion in Psychiatry · doi:10.1097/yco.0b013e328356bd57 · Cited by 18
Ngo, V. K., Wagner, G. J., Nakasujja, N., Dickens, A., Aunon, F. M., & Musisi, S. (2014) · International Journal of STD & AIDS · doi:10.1177/0956462414564606 · Cited by 19
Taylor, G. M. J., Girling, A. J., McNeill, A. D., & Aveyard, P. N. (2015) · BMJ Open · doi:10.1136/bmjopen-2015-008774 · Cited by 17
Common Questions About the Pharmacologic Management of Depression in Adults.
Kovich, H., & DeJong, A. (2015) · PubMed · Cited by 18
Barnard, K. D., & Lloyd, C. E. (2012) · Springer eBooks · doi:10.1007/978-0-85729-573-6 · Cited by 34
Contemporary spiritual meditation: Practices and outcomes.
Wachholtz, A., & Austin, E. T. (2012) · American Psychological Association eBooks · doi:10.1037/14045-017 · Cited by 20
Murphy, J., Blais, M. A., Lee, B.-E., McCarthy, A. E., Kamin, H., Masek, B., & Jellinek, M. S. (2015) · Clinical Child Psychology and Psychiatry · doi:10.1177/1359104513494872 · Cited by 20
The Changing Face of U.S. Mental Health Care
Druss, B. G. (2010) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2010.10091258 · Cited by 19
Tovar-Perdomo, S., McGirr, A., Van den Eynde, F., Rodrigues dos Santos, N., & Berlim, M. T. (2017) · Journal of Affective Disorders · doi:10.1016/j.jad.2017.03.075 · Cited by 18
Harvey, P., den Eynde, F. V., Zangen, A., & Berlim, M. T. (2013) · Neurocase · doi:10.1080/13554794.2013.860173 · Cited by 19
Nicotine restores functional connectivity of the ventral attention network in schizophrenia
Smucny, J., D, A. O. M., & Tregellas, J. R. (2016) · Neuropharmacology · doi:10.1016/j.neuropharm.2016.04.015 · Cited by 17
Mizutani, M., Sano, T., Ohira, M., & Takao, M. (2022) · Psychiatry and Clinical Neurosciences · doi:10.1111/pcn.13436 · Cited by 17
Stewart, T. D., Hatch, A., Largay, K., Sheehan, J. J., Marler, S. V., Berman, R., & Nelson, J. C. (2014) · Journal of Affective Disorders · doi:10.1016/j.jad.2014.03.017 · Cited by 17
Metadata
- Authors
- Fournier, J. C., DeRubeis, R. J., Hollon, S. D., Dimidjian, S., Amsterdam, J. D., Shelton, R. C., & Fawcett, J.
- Affiliations
- University of Pennsylvania (US)
- University of New Mexico (US)
- Venue
- JAMA
- Publisher
- American Medical Association (AMA)
- Published
- 2010-01-06
- Volume
- 303
- Issue
- 1
- Pages
- 47
- ISSN
- 0002-9955 (ISSN-L)
- 0098-7484
- PMC
- PMC3712503
- OpenAlex
- W2004762037
- Cited by
- 2,009
- References
- 56
- Citations by year
- 2026: 54 · 2025: 72 · 2024: 89 · 2023: 70 · 2022: 81 · 2021: 134 · 2020: 81 · 2019: 111 · 2018: 143 · 2017: 128 · 2016: 112 · 2015: 149 · 2014: 154 · 2013: 170 · 2012: 172
- FWCI
- 144.95
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- JAMA (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- Bristol-Myers Squibb
- Eli Lilly and Company
- Pfizer
- GlaxoSmithKline
- Sanofi
- National Alliance for Research on Schizophrenia and Depression
- Universiteit Maastricht
- National Institute of Mental Health (K24MH001741, R10 MH50129, R01MH060998, K02MH001697, R10MH055875, R10MH055877)
- Janssen Pharmaceuticals
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Health Sciences › Medicine › Psychiatry and Mental health › Mental Health Treatment and Access
- Social Sciences › Psychology › Experimental and Cognitive Psychology › Anxiety, Depression, Psychometrics, Treatment, Cognitive Processes
- Keywords
- antidepressants, major depressive disorder, depression severity, placebo response, Hamilton Depression Rating Scale, treatment effect heterogeneity, mild depression, antidepressant efficacy
- MeSH terms
- Adult, Antidepressive Agents, Depression, Major Depressive Disorder, Humans, Placebo Effect, Randomized Controlled Trials as Topic, Treatment Outcome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
